Cargando…

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates

Newborns are highly susceptible to infections; however, the underlying mechanisms that regulate the anti-microbial T-helper cells shortly after birth remain incompletely understood. To address neonatal antigen-specific human T-cell responses against bacteria, Staphylococcus aureus (S. aureus) was us...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majer, Christiane, Lingel, Holger, Arra, Aditya, Heuft, Hans-Gert, Bretschneider, Dirk, Balk, Silke, Vogel, Katrin, Brunner-Weinzierl, Monika C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051326/ https://www.ncbi.nlm.nih.gov/pubmed/36982735 http://dx.doi.org/10.3390/ijms24065662

Ejemplares similares

PD-1 limits differentiation and plasticity of Tc17 cells
por: Arra, Aditya, et al.
Publicado: (2023)

Bifidobacteria shape antimicrobial T-helper cell responses during infancy and adulthood
por: Vogel, Katrin, et al.
Publicado: (2023)

Unique autoantibody prevalence in long-term recovered SARS-CoV-2-infected individuals
por: Lingel, Holger, et al.
Publicado: (2021)

Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults
por: Arra, Aditya, et al.
Publicado: (2021)

IL‐13 determines specific IgE responses and SARS‐CoV‐2 immunity after mild COVID‐19 and novel mRNA vaccination
por: Meltendorf, Stefan, et al.
Publicado: (2022)

Developmental induction of human T-cell responses against Candida albicans and Aspergillus fumigatus
por: Vogel, Katrin, et al.
Publicado: (2018)

CTLA-4 and PD-1 Control of T-Cell Motility and Migration: Implications for Tumor Immunotherapy
por: Brunner-Weinzierl, Monika C., et al.
Publicado: (2018)

Migration of Th1 Lymphocytes Is Regulated by CD152 (CTLA-4)-Mediated Signaling via PI3 Kinase-Dependent Akt Activation
por: Knieke, Karin, et al.
Publicado: (2012)

CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation
por: Lingel, Holger, et al.
Publicado: (2017)

Preventing Atopic Diseases During Childhood – Early Exposure Matters
por: Pierau, Mandy, et al.
Publicado: (2021)

Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells
por: Zhao, Yunlong, et al.
Publicado: (2018)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1
por: D’Alterio, Crescenzo, et al.
Publicado: (2019)

Multiple functions for CD28 and cytotoxic T lymphocyte antigen-4 during different phases of T cell responses: implications for arthritis and autoimmune diseases
por: Brunner-Weinzierl, Monika C, et al.
Publicado: (2004)

Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
por: Shen, Chunyi, et al.
Publicado: (2021)

Circulating Exhausted PD-1(+)CD39(+) Helper CD4 T Cells Are Tumor-Antigen-Specific and Predict Response to PD-1/PD-L1 Axis Blockade
por: Martinez-Gomez, Carlos, et al.
Publicado: (2022)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

Early changes in the metabolic profile of activated CD8(+) T cells
por: Cammann, Clemens, et al.
Publicado: (2016)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia
por: Ries, Jutta, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
por: Yang, Ching-Yao, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Microglial PD‐1 stimulation by astrocytic PD‐L1 suppresses neuroinflammation and Alzheimer’s disease pathology
por: Kummer, Markus P, et al.
Publicado: (2021)

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma
por: Göbel, Holger H., et al.
Publicado: (2022)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
por: Niu, Mengke, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ubeil9tganlictsh15u0c6a5m1